Abbreviations FTD: frontotemporal dementia GRN: progranulin MAPT: microtubule-associated protein tau C9orf72 : chromosome 9 open reading frame 72 bvFTD: behavioural variant of frontotemporal dementia MRI: magnetic resonance imaging CNCs: cognitively normal controls DBM: deformation-based morphometry FTLDNI: frontotemporal lobar degeneration neuroimaging initiative T1-w: T1 weighted GENFI: Genetic frontotemporal dementia initiative MMSE: Mini mental state examination MOCA: Montreal cognitive assessment FTLD-CDR: Frontotemporal lobar degeneration Clinical Dementia Rating score CGI: Clinical global impression FRS: Frontotemporal dementia rating scale FDR: False Discovery Rate PCA: Principal component analysis PCs: Principal components SF: Semantic fluency ROC: Receiver operating characteristic curves AUC: Area under the curve LR+: positive likelihood ratio LR-: negative likelihood ratio Abstract INTRODUCTION: Brain structural imaging is paramount for the diagnosis of behavioral variant of frontotemporal dementia (bvFTD), but it has low sensitivity leading to erroneous or late diagnosis.
Introduction
The heterogeneity of frontotemporal dementia (FTD) is frequently considered a hallmark of the disease with significant variations in heritability, pathology and clinical presentations (1) . First, although most cases of FTD are sporadic, there is a positive familiar history in 30-50% of the cases, and 10-30% are caused by an autosomal dominant mutation (most commonly progranulin -GRN-, microtubule-associated protein Tau -MAPT-and chromosome 9 open reading frame 72 -C9orf72-) (2, 3) . Second, in terms of the underlying pathology, there are three main groups according to the major protein involved, all of which are characterized by selective degeneration of the frontal and temporal lobes: Tau, transactive response DNA-binding protein of 43 kDa -TDP-43-, and the tumor associated protein fused in sarcoma -FUS-. (4, 5) Finally, regarding its clinical presentation, FTD is divided into three major clinical syndromes: the behavioral variant (bvFTD) and two language variants (Semantic Dementia and Non-Fluent Primary Progressive Aphasia). As the initially focal brain involvement spreads to involve larger regions in the frontal and temporal lobes, the symptoms of the three variants described can converge (5) . Yet, there is also a considerable overlap between FTD and other neurodegenerative diseases; i.e. some patients with FTD may develop motor neuron disease, or symptoms of a Parkinsonian disorder (6) .
Due to the aforementioned heterogeneity in pathology and heritability, as well as the syndromic overlap with psychiatric disorders and other dementias, a confirmed bvFTD diagnosis is often difficult to achieve in the absence of a dominant genetic mutation. Indeed, although brain imaging with magnetic resonance imaging (MRI) is paramount to increase the level of diagnostic confidence, it lacks sensitivity, particularly in the initial stages of the disease, leading to erroneous or late diagnosis (7, 8) .
It has been recognized that the pattern of atrophy in sporadic bvFTD differed but also shared some similarities from that observed in mutation carriers. While frontal -particularly the anterior cingulate gyrus-and anterior temporal atrophy was associated to sporadic bvFTD, genetic variants showed distinct but overlapping patterns of atrophy (9) (10) (11) . In MAPT mutation carriers, atrophy predominantly affects the anterior and medial temporal lobes, orbitofrontal lobe and insula; in GRN mutation carriers atrophy in the dorsolateral and ventromedial prefrontal, superolateral temporal and lateral parietal lobes as well as the anterior cingulate, insula, precuneus and striatum has been described; and C9orf72 carriers showed relatively widespread cortical atrophy including posterior areas, and with particular involvement of the thalamus and superoposterior cerebellum (11) .
Lately, machine learning techniques have been applied to distinguish between bvFTD and Cognitively Normal Subjects (CNCs), Alzheimer Disease or other psychiatric and neurologic disorders on an individual level using MRI based features (12) (13) (14) (15) (16) (17) (18) (19) (20) . Studies vary greatly on the subjects included and the methodology. In the present study, we developed a Random Forest classifier (21) using features derived from Deformation Based Morphometry (DBM) maps to identify bvFTD subjects from CNCs. To ensure the generalizability of the results, the machine learning model was trained on a mainly sporadic cohort and tested in a held-out population of genetic bvFTD, therefore relying on one of the gold standards for bvFTD diagnosis (i.e., definite bvFTD)(7).
Materials and Methods

Participants
A total of 515 subjects were examined in this study. The first cohort ('training cohort') included bvFTD patients and CNCs from the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI) database who had T1-weighted (T1w) MRI scans matching with each clinical visit. Data was accessed and downloaded through the LONI platform in August 2018. The inclusion criteria for bvFTD patients was a diagnosis of possible or probable bvFTD according to the FTD consortium criteria (7) , resulting in 70 patients with bvFTD and 123 CNCs in our study.
The FTLDNI was funded through the National Institute of Aging and started in 2010. The primary goals of FTLDNI are to identify neuroimaging modalities and methods of analysis for tracking frontotemporal lobar degeneration (FTLD) and to assess the value of imaging versus other biomarkers in diagnostic roles. The project is the result of collaborative efforts at three sites in North America. For up-to-date information on participation and protocol, please visit: http://4rtni-ftldni.ini.usc.edu/ The second cohort ('validation cohort') included bvFTD patients and CNCs from the third data freeze (12/2017) of the Genetic Frontotemporal Dementia Initiative 2 (GENFI2http://genfi.org.uk/) (22) , which consists of 23 centres in the UK, Italy, The Netherlands, Sweden, Portugal and Canada. GENFI2 participants included known symptomatic carriers of a pathogenic mutation in C9orf72, GRN or MAPT and their first-degree relatives who are at risk of carrying a mutation, but who did not show any symptoms (i.e., presymptomatic). Non-carriers were first-degree relatives of symptomatic carriers who did not carry the mutation. The inclusion and exclusion criteria are described in detail elsewhere (22) . Since the aim of the present study was to differentiate bvFTD patients from CNCs, presymptomatic carriers and symptomatic carriers whose clinical diagnosis was other than bvFTD were excluded. Non-carriers were considered as CNCs for the purpose of this study. This validation cohort contained 75 patients with bvFTD and 247 CNCs.
Clinical assessment
All FTLDNI subjects were regularly assessed every six-months for clinical characteristics 
Image acquisition and preprocessing
For the FTLDNI training cohort, 3.0T MRIs were acquired at three sites. In all sites, a volumetric MPRAGE sequence was used to acquire T1w images of the entire brain. The acquisition parameters of the T1w images, using volumetric MPRAGE sequence, were RT/ET/IT: 2.3/3/900 ms, flip angle 9°, matrix 256x240, slice thickness 1mm, voxel size 1x1mm.
For the GENFI2 validation cohort, participants underwent volumetric T1w MRI at multiple centers, according to the GENFI imaging protocol. Sites used different types of scanners:
Siemens Trio 3T, SiemensSkyra3T, Siemens1.5T, Phillips3T, General Electric (GE) 1.5T and GE 3T. Scan protocols were designed at the outset of the study to ensure adequate matching between the scanners and image quality control.
The T1w scans of the subjects were pre-processed through our longitudinal pipeline (23) that included image denoising (24) , intensity non-uniformity correction (25) , and image intensity normalization into range (0−100) using histogram matching. Each native T1w volume from each timepoint was linearly registered first to the subject-specific template which was then registered to the ICBM152 template (26, 27) . All images were then non-linearly registered to the ICBM152 template using ANTs diffeomorphic registration pipeline (28) . The images were visually assessed by two experienced raters to exclude cases with significant imaging artifacts (e.g. motion, incomplete field of view) or inaccurate linear/nonlinear registrations. This visual assessment was performed without any knowledge of the diagnosis. Out of 1724 scans, only 43 (2.5%, 36 scans in GENFI2, and 7 in FTLDNI) did not pass this visual quality control. For the purpose of this study, scans from subjects other than bvFTD or CNCs, or those that did not have a matching clinical visit were excluded from this analysis. This resulted in a total of 515 subjects that were included in this study.
Deformation based morphometry
DBM analysis was performed using Montreal Neurological Institute (MNI) MINC tools (23) .
The principle of DBM is to warp each individual scan to the template by introducing highdimensional deformations (29, 30) . Then, the morphological differences between the two are encoded in the deformations estimated for the warp. The local deformation obtained from the non-linear transformations was used as a measure of tissue expansion or atrophy by computing the determinant of the Jacobian at each voxel. Local contractions can be interpreted as shrinkage (e.g., tissue atrophy) and local expansions are often related to ventricular or sulci enlargement.
DBM was used to assess both voxel-wise and atlas-based cross-sectional group related volumetric differences.
Classification bvFTD versus CNCs
To obtain a region of interest reflecting the difference between bvFTD and CNCs, a voxel-wise mixed effects model analysis was performed in the training dataset to assess the pattern of volumetric change according to diagnosis. The mixed effects model included age as a continuous fixed variable and diagnosis and sex as fixed categorical variables. Subject was included as a categorical random variable. The resulting maps were corrected for multiple comparisons using False Discovery Rate (FDR) with a P value < .05 threshold to identify regions associated with differences between bvFTD and CNCs; i.e. the diagnosis variable in the mixed effects model. A principal component analysis (PCA) was then performed on the DBM voxels within this region of interest. To avoid any leakage, only the training data was used for this PCA. Two sets of features were then used to train a random forests classifier (21) with 500 trees: 1) the first five principal components (PCs) as well as age and sex, and 2) the first five PCs, age, sex, and a neuropsychological score. The Semantic Fluency score (SF) was used as the cognitive score feature since it is a reliable simple bedside test associated with executive and language deficits in bvFTD (31) and was available for most of the subjects in both training and validation datasets.
Executive deficits are considered a core characteristic of FTD, though in themselves, are insufficient to establish a diagnosis (32, 33) . Classifications were run using DBM in isolation and DBM + SF. Ten-fold cross validation was used to assess the performance of the classifier within the training data.
To perform classification on the held-out GENFI2 validation dataset, the coefficients calculated based on the PCA on the training dataset were used to calculate the first five PCs features for the subjects from the validation dataset. Using the random forest classifier that was trained on FTLDNI, we then classified all the subjects from the validation dataset as either bvFTD or CNCs. A probability score was also obtained from the random forest classifier, indicating the likelihood of each observation belonging to the bvFTD class. The mixed effects modelling, PCA, and random forest classification were carried out using MATLAB (version R2017b).
Statistical analyses
All statistical analyses were also conducted using MATLAB (version R2017b). Two-sample t-Tests were conducted to examine demographic and clinical variables at baseline. Categorical variables were analysed using chi-square analyses. Results are expressed as mean ± standard deviation and median [interquartile range] as appropriate. Receiver Operator Characteristics (ROC) analysis was used to define sensitivity and specificity at different cut-points within the validation cohort. The optimal cut-point was estimated by the use of Youden index (J= Sensitivity+Specificity-1). Positive and negative likelihood ratios were also estimated for different cut points. Table 1 shows the demographic and cognitive testing performances in bvFTD and CNCs. There was no difference in age between bvFTD patients and CNCs (62±6 and 63±6 years respectively, P value = 0.36), but there was a higher proportion of males in bvFTD patients than CNCs (67% vs 43%, P value = .001). As expected, bvFTD subjects showed greater cognitive and functional impairment: significant differences were found between the two cohorts in MMSE, FTLD-CDR, MOCA, letter fluency Z-score and semantic fluency Z-score (all P value < .001).
Results
Demographics
Demographic differences and cognitive testing performances between patients and controls for the GENFI cohort are also shown in Table 1 . Considering the CNCs from this dataset comes from non-carrier members of families at risk of genetic mutation related to FTD, they were, as expected, significantly younger than bvFTD subjects. The mean age was 48±14 years for CNCs and 64±8 years for bvFTD (P value < .001). The mean estimated disease duration for the bvFTD group was 5.2±5.7 years. Compared to non-carriers, bvFTD subjects showed greater cognitive and functional impairment. Significant differences were found between the two cohorts in MMSE, FTLD-CDR, MOCA, FRS, letter fluency Z-score and semantic fluency Z-score (P value < .001). Regarding the mutated gene, half of the bvFTD subjects carried a C9orf72 mutation, while 22.7% and 25.3% belonged to the MAPT and GRN groups respectively. 
Voxel-wise DBM group differences.
Greater gray and white matter atrophy were found in the medial and inferior lateral portions of the frontal lobes as well as dorsolateral prefrontal cortex, insula, basal ganglia, medial and anterior temporal regions bilaterally and regions of brainstem and cerebellum in bvFTD.
Correspondingly, volume increase was shown in the ventricles and sulci, being more evident in frontal horns and lateral sulcus (34).
Random forest classification
Cross-validation results within the training cohort
The accuracy achieved for discrimination between bvFTD and CNCs using solely morphometric MRI features (DBM) was 89%, with a sensitivity of 82% and specificity of 93%. When adding one cognitive score (i.e., DBM+SF) the classifier accuracy reached 94%, with 89% sensitivity and 98% specificity.
Classification within the validation cohort using solely DBM and DBM + SF
The application of the random forest classification model based on the training cohort to the validation cohort resulted in an accuracy of 88% when discriminating bvFTD patients from
CNCs. Sensitivity and specificity were 81% and 92%, respectively using a probability score with an optimal cut point of 0. Figure 1 . Figure 2 shows the true positive rates for bvFTD and CNCs according the probability score for DBM (panel A) and DBM+SF (panel B). Table 2 shows the corresponding accuracy, sensitivity, specificity and likelihood ratios for the two models (DBM and DBM+SF) using different thresholds on the probability scores (e.g., for probability scores > 0.4). Table 2 . Classification performance using DBM and DBM + SF NOTE: *Performances for each probability score threshold above which a subject is identified as bvFTD. Shaded rows correspond to the optimal cut-point estimated by Youden index. Abbreviations: DBM: deformation-based morphometry; SF: semantic fluency score; LR+: positive likelihood ratio; LR-: negative likelihood ratio.
False negative cases within the validation cohort
The classification using DBM resulted in 19% of false negatives. These subjects were significantly younger than the bvFTD subjects correctly classified (57±10 vs. 66±7 years respectively, P value < .001) and the estimated time from onset was also smaller (2±7 years vs 6±5 years; P value = .01). However, no significant differences were found in FTLD-CDR score between true positives and false negatives (P value = .07). The distribution of the genetic mutations did not show significant differences either between the false negatives and true 
False positive cases within the validation cohort
Only 10 out of 247 CNCs (4%) were erroneously classified as bvFTD. These subjects were significantly older than the subjects accurately classified as healthy subjects (70±12 years vs.
47±13 years, respectively; P value < .001). No significant differences were found in the mean FTLD-CDR score (P value = .9). There was a small difference between the MMSE score for the false positives (28.27±2.2) and for true negatives (29.4±1; P value < .001).
Defining strategic cut-points
Three cut-offs for both DBM and DBM+SF were defined by giving consideration to the sensitivity, specificity, positive and negative likelihood ratios of different points of the ROC: 1) the optimal cut-point according to Youden index; 2) a sensitive (i.e., "rule-out") cut-point; and 3) a specific (i.e., "rule-in") cut-point ( Figure 3 ). The sensitivity, specificity, LR-and LR+ expressed in the figure were estimated for each of these defined cut-points (e.g., for probability score = 0.4)
Proposed thresholds for clinical decision-making for each classifier according to their likelihood ratios are proposed in Figure 3 (lower panels). A LR-<0.1 allows to reliably exclude (i.e., ruleout) bvFTD when the probability score is below 0.2 and 0. 
Discussion
In the present study we built a random forest classifier using morphometric MRI features for the individual prediction of bvFTD. The main findings are: 1) our random forest algorithm yielded areas under the curve of 0.90 and 0.92 using DBM and DBM+SF, respectively, in the independent validation cohort of genetically confirmed bvFTD cases; 2) the inclusion of a simple cognitive score (SF) improved the accuracies and specificity regardless of the probability threshold chosen, while reducing the false negative rate for probability scores > 0.5; 3) we provide three cut-off values (a "statistically optimal" cut-point, a sensitive ("rule-out") cut-point and a specific ("rule-in") cut-point) for both DBM and DBM+SF classifiers; and 4) our results
show good positive and negative likelihood ratios proving its reliability in ruling in and out the disease.
The likelihood ratio is the percentage of patients with a given test result divided by the percentage of controls with the same results. Meaning that ill people should be more likely to have an abnormal result of a given test than healthy individuals (35, 36) . For DBM only classifier in the independent validation cohort, the optimal threshold yielded an area under the curve (AUC) of 0.9 with 81% sensitivity and 92% specificity leading to a positive LR+ of 10.13 and negative LR-of 0.21. Whereas, the AUC, sensitivity and specificity using the DBM+SF model were 0.92, 79% and 96%, respectively. These values result in LR+ of 19.75 and LR-of 0.22. To keep in mind, a test is moderately good at ruling in disease when LR+ is greater than 2 and very good at doing it when LR+ is greater than 10 (37) . Furthermore, a test is moderately good at ruling out the disease with LR-below 0.5 and very good below 0.1. Hence, using the optimal thresholds, both models are very good at excluding non bvFTD subjects and moderately good at confirming the disease.
Our results show that the random forest classifier we developed in our training cohort can accurately predict bvFTD in individual subjects in a completely independent validation cohort coming from a different and independent database. Furthermore, the GENFI2 validation cohort includes bvFTD patients with a definite diagnosis (positive genetic mutation). Of note, our algorithm was able to accurately classify patients with genetic bvFTD even though they tend to have more atypical atrophy patterns (11) . The performance of our classifier is superior than the performance reported in several articles that have analyzed the standard diagnostic methods currently used in the clinical practice. Within a pathology-confirmed cohort the sensitivity reported for the revised diagnostic criteria for bvFTD was 86% for possible diagnosis and 75%
for probable bvFTD (with neuroimaging support) (7) . However, these criteria reported a sensitivity of 85% and specificity of 27% for possible bvFTD diagnosis in a clinically relevant cohort of patients with mixed behavioral changes, reaching 82% specificity when adding a compatible MRI scan (38) . Within a cohort with late onset behavioral disorders, 70% sensitivity and 93% specificity have been reported for structural MRI alone for bvFTD assessed by an experienced neuroradiologist (8) . The latter results have comparable positive and negative likelihood ratios to ours, even though our method does not rely on the expertise of the radiological observer.
Previous studies classified bvFTD from a control group (12) (13) (14) (15) (16) . The best AUC was reported by Raamana et al (AUC 0.938, 100% sensitivity and 88% specificity). However, the main limitation of that study is that the bvFTD diagnosis from the validation cohort was based on clinical criteria (39) . Contrarily, the bvFTD subjects from our validation cohort are known carriers of a pathogenic mutation and have therefore, definite bvFTD diagnosis.
The performance of the classifier was tested on a held-out database which included multi-center and multi-scanner data from different scanner models of both 1.5T and 3T field strengths. This further reinforces the generalizability (i.e., external validity) of our results and ensures their applicability in a clinical scenario with different scanners, even with different magnetic field strengths. This certainly constitutes one of the main strengths of this study along with the fact that our performance was estimated using one of the gold standards for FTD diagnosis (i.e., definite FTD supported by the presence of a pathogenic mutation). Of significant value, our algorithm is based on standard structural T1w MRI and a simple cognitive test that are already routinely acquired clinically, making for strong translational potential. On the other hand, the main limitation is that these results are yet to be validated prospectively in a clinically representative cohort including patients with diverse primary psychiatric disorders (a common differential diagnosis from bvFTD) (40) . The classification accuracy also remains to be demonstrated in cohorts with other types of dementias and cardiovascular comorbidities, as these were uncommon in our dataset and could have influenced our very high specificity. Finally, in our results the false negatives/positives were significantly younger/older than the subjects that were correctly classified. This is likely due to the fact that the age range for the validation dataset (GENFI: minimum age: 39, maximum age:79) was larger than the training set (FTLDNI, minimum age 46, maximum age 75). Subjects that were outside the operating range of the classifier were therefore more likely to be misclassified. Adding subjects with similar ages to the training dataset will likely improve the results. In addition, specifically for the false negative cases, although the difference did not reach statistical significance (p=0.07), the false negatives had lower FTLD-CDR scores than the true positive cases, implying an earlier stage of the disease. It is plausible that such subjects with milder symptoms were not as well represented in NIFD given the difficulty of diagnosing bvFTD in the very mild stages when there is no known genetic mutation.
To conclude, we propose an automatic method using structural MRI alone (already available and routinely used in the clinic) and including a simple cognitive test that could be administered by any physician in few minutes for reliable individual prediction of bvFTD at the individual subject level. If validated in a prospective study, this algorithm has the potential to improve diagnostic accuracy, particularly in setting without access to specialized FTD care.
